Dana E. Moseson

1.0k total citations
27 papers, 789 citations indexed

About

Dana E. Moseson is a scholar working on Pharmaceutical Science, Materials Chemistry and Molecular Biology. According to data from OpenAlex, Dana E. Moseson has authored 27 papers receiving a total of 789 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pharmaceutical Science, 17 papers in Materials Chemistry and 8 papers in Molecular Biology. Recurrent topics in Dana E. Moseson's work include Drug Solubulity and Delivery Systems (22 papers), Crystallization and Solubility Studies (15 papers) and Protein purification and stability (8 papers). Dana E. Moseson is often cited by papers focused on Drug Solubulity and Delivery Systems (22 papers), Crystallization and Solubility Studies (15 papers) and Protein purification and stability (8 papers). Dana E. Moseson collaborates with scholars based in United States, Japan and Belgium. Dana E. Moseson's co-authors include Lynne S. Taylor, Alexander J. Moseson, Michel W. Barsoum, Umesh S. Kestur, Sugandha Saboo, Tze Ning Hiew, Stephen P. Beaudoin, Andrew S. Parker, Keisuke Ueda and Patrick Augustijns and has published in prestigious journals such as ACS Applied Materials & Interfaces, Journal of Controlled Release and International Journal of Pharmaceutics.

In The Last Decade

Dana E. Moseson

27 papers receiving 776 citations

Peers

Dana E. Moseson
P. Sakellariou United Kingdom
E. Kougoulos United Kingdom
H Nyqvist Sweden
Michael Juhnke Switzerland
Shaun Fitzpatrick United Kingdom
Bao Chen China
P. Sakellariou United Kingdom
Dana E. Moseson
Citations per year, relative to Dana E. Moseson Dana E. Moseson (= 1×) peers P. Sakellariou

Countries citing papers authored by Dana E. Moseson

Since Specialization
Citations

This map shows the geographic impact of Dana E. Moseson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dana E. Moseson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dana E. Moseson more than expected).

Fields of papers citing papers by Dana E. Moseson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dana E. Moseson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dana E. Moseson. The network helps show where Dana E. Moseson may publish in the future.

Co-authorship network of co-authors of Dana E. Moseson

This figure shows the co-authorship network connecting the top 25 collaborators of Dana E. Moseson. A scholar is included among the top collaborators of Dana E. Moseson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dana E. Moseson. Dana E. Moseson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Moseson, Dana E., et al.. (2024). Dissolution, phase behavior and mass transport of amorphous solid dispersions in aspirated human intestinal fluids. Journal of Pharmaceutical Sciences. 114(1). 336–349. 2 indexed citations
2.
Badruddoza, Abu Zayed Md, et al.. (2024). Role of rheology in formulation and process design of hot melt extruded amorphous solid dispersions. International Journal of Pharmaceutics. 664. 124651–124651. 7 indexed citations
3.
Moseson, Dana E., et al.. (2024). Trends in amorphous solid dispersion drug products approved by the U.S. Food and Drug Administration between 2012 and 2023. International Journal of Pharmaceutics X. 7. 100259–100259. 43 indexed citations
4.
Ueda, Keisuke, Dana E. Moseson, & Lynne S. Taylor. (2024). Amorphous solubility advantage: Theoretical considerations, experimental methods, and contemporary relevance. Journal of Pharmaceutical Sciences. 114(1). 18–39. 27 indexed citations
5.
Moseson, Dana E., Na Li, Jukka Rantanen, Keisuke Ueda, & Geoff G. Z. Zhang. (2024). Professor Lynne S. Taylor: Scientist, educator, and adventurer. Journal of Pharmaceutical Sciences. 114(1). 2–9. 1 indexed citations
6.
Moseson, Dana E., et al.. (2024). Dissolution of copovidone-based amorphous solid dispersions: Influence of atomic layer coating, hydration kinetics, and formulation. Journal of Pharmaceutical Sciences. 114(1). 323–335. 1 indexed citations
7.
Chen, Yun‐Chu, et al.. (2023). Control of drug release kinetics from hot-melt extruded drug-loaded polycaprolactone matrices. Journal of Controlled Release. 359. 373–383. 14 indexed citations
8.
Moseson, Dana E., Ziyi Cao, Miaojun Wang, et al.. (2022). Impact of Aluminum Oxide Nanocoating on Drug Release from Amorphous Solid Dispersion Particles. Molecular Pharmaceutics. 20(1). 593–605. 11 indexed citations
9.
Moseson, Dana E., et al.. (2022). Atomic Layer Coating to Inhibit Surface Crystallization of Amorphous Pharmaceutical Powders. ACS Applied Materials & Interfaces. 14(36). 40698–40710. 17 indexed citations
10.
Moseson, Dana E., Tze Ning Hiew, Yongchao Su, & Lynne S. Taylor. (2022). Formulation and Processing Strategies which Underpin Susceptibility to Matrix Crystallization in Amorphous Solid Dispersions. Journal of Pharmaceutical Sciences. 112(1). 108–122. 22 indexed citations
11.
Chen, Yun‐Chu, Dana E. Moseson, Sarena D. Horava, et al.. (2022). Development of hot-melt extruded drug/polymer matrices for sustained delivery of meloxicam. Journal of Controlled Release. 342. 189–200. 18 indexed citations
12.
Moseson, Dana E., et al.. (2021). Crystallization Kinetics in Fasted-State Simulated and Aspirated Human Intestinal Fluids. Crystal Growth & Design. 21(5). 2807–2820. 10 indexed citations
13.
Moseson, Dana E., et al.. (2021). Impact of Polymer Type on Thermal Degradation of Amorphous Solid Dispersions Containing Ritonavir. Molecular Pharmaceutics. 19(1). 332–344. 14 indexed citations
14.
Moseson, Dana E., et al.. (2021). Amorphous Solid Dispersions Containing Residual Crystallinity: Competition Between Dissolution and Matrix Crystallization. The AAPS Journal. 23(4). 69–69. 42 indexed citations
15.
Mugheirbi, Naila A., Laura I. Mosquera-Giraldo, Dana E. Moseson, et al.. (2021). Interaction of Polymers with Enzalutamide Nanodroplets—Impact on Droplet Properties and Induction Times. Molecular Pharmaceutics. 18(3). 836–849. 17 indexed citations
16.
Moseson, Dana E., et al.. (2020). Application and limitations of thermogravimetric analysis to delineate the hot melt extrusion chemical stability processing window. International Journal of Pharmaceutics. 590. 119916–119916. 50 indexed citations
17.
Moseson, Dana E., Andrew S. Parker, Stephen P. Beaudoin, & Lynne S. Taylor. (2020). Amorphous solid dispersions containing residual crystallinity: Influence of seed properties and polymer adsorption on dissolution performance. European Journal of Pharmaceutical Sciences. 146. 105276–105276. 54 indexed citations
18.
Saboo, Sugandha, Dana E. Moseson, Umesh S. Kestur, & Lynne S. Taylor. (2020). Patterns of drug release as a function of drug loading from amorphous solid dispersions: A comparison of five different polymers.. European Journal of Pharmaceutical Sciences. 155. 105514–105514. 75 indexed citations
20.
Moseson, Dana E. & Lynne S. Taylor. (2018). The application of temperature-composition phase diagrams for hot melt extrusion processing of amorphous solid dispersions to prevent residual crystallinity. International Journal of Pharmaceutics. 553(1-2). 454–466. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026